<p>Cellebrite DI（纳斯达克代码：CLBT）刚刚发布了季度更新，市场对此反应热烈，股价上涨约 20%，投资者对其在 Guardian 调查平台上的强劲执行和加速势头表示满意。</p>
<p>查看我们对 Cellebrite DI 的最新分析。</p>
<p>这次盈利的激增是在过去一个月股价回报 18.7% 和 90 天涨幅 7% 的基础上，尽管年初至今的股价回报仍为负值，且一年期的总股东回报略有亏损。同时，三年期总股东回报超过 300% 显示出长期故事的强大，暗示随着投资者重新关注 Guardian 的增长、Corellium 的整合以及潜在的联邦和北约相关的上行空间，势头正在重建。</p>
<p>如果 Cellebrite 的表现让你重新考虑投资机会，这可能是探索高增长科技和人工智能股票的好时机，这些股票正在塑造下一波数字调查和防御技术。</p>
<p>随着收入和盈利仍在复合增长，且股票交易价格大幅低于分析师目标价，关键问题是此次重置是否使 CLBT 被低估，还是市场已经在定价下一轮增长。</p>
<h2>最受欢迎的叙述：26% 被低估</h2>
<p>叙述的公允价值为 24.71 美元，而最后收盘价为 18.28 美元，估值案例在很大程度上依赖于更快的增长和更高的利润率。</p>
<blockquote>
<p><em>持续向基于订阅的经常性收入模式转型，现有超过 90% 的收入来自订阅，且 SaaS/云渗透率不断提高，改善了收入的可见性、可预测性和运营杠杆。这已经转化为更高的 EBITDA 和自由现金流利润率，且在当前估值中可能被低估。</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>要了解这种信心差距背后的数学，包括增长前景、利润率扩张和未来收益倍数，探索完整叙述。</p>
<p><strong>结果：公允价值为 24.71 美元（被低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，对美国联邦合同的高度依赖以及在合法访问工具中日益激烈的竞争可能会减缓 ARR 增长并压缩溢价估值案例。</p>
<p>了解 Cellebrite DI 叙述的关键风险。</p>
<h2>另一种看待价值的方法</h2>
<p>虽然叙述表明 Cellebrite 被低估 26%，但我们的 SWS DCF 模型则有不同看法，公允价值接近 13.51 美元，而当前股价为 18.28 美元。这意味着该股票实际上被高估。你更信任哪个视角来判断下一步？</p>
<p>深入了解 SWS DCF 模型如何得出其公允价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3faf6e74-6124-464a-beb5-e211fb138330/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3faf6e74-6124-464a-beb5-e211fb138330/chart/dcf"/></p>
<p>截至 2025 年 12 月的 CLBT 折现现金流</p>
<p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看 Cellebrite DI）。我们展示了完整的计算过程。你可以在你的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 907 只基于现金流的被低估股票。如果你保存一个筛选器，我们甚至会在新公司匹配时提醒你——这样你就不会错过潜在机会。</p>
<h2>构建你自己的 Cellebrite DI 叙述</h2>
<p>如果这个前景与你的观点不完全一致，自己深入数字，几分钟内构建一个量身定制的叙述，按你的方式进行。</p>
<p>一个好的起点是我们的分析，强调投资者对 Cellebrite DI 的三个关键回报的乐观态度。</p>
<h2>准备好更多投资想法了吗？</h2>
<p>在市场下一个重大变动让你旁观之际，利用你的研究工作，排定下一个机会，使用针对性的筛选器。</p>
<ul>
<li>通过审查这些 907 只基于现金流的被低估股票，利用潜在的错误定价，这些股票将强大的基本面与有吸引力的估值相结合，在情绪完全追赶之前。</li>
<li>通过关注这 30 只支持诊断、患者结果和医院效率的医疗 AI 股票，探索结构性增长趋势，这些股票将在未来十年内发挥作用。</li>
<li>通过评估这 81 只围绕区块链基础设施、支付和数字资产网络构建真实业务的加密货币和区块链股票，为金融创新做好准备。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容一般。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

CLBT

<p>Cellebrite DI 的股价在发布积极的财报和其 Guardian 平台增长后上涨了 20%。尽管年初至今的回报为负，但三年期的股东回报超过 300%。分析师们对 CLBT 在 24.71 美元时是被低估还是在 13.51 美元时被高估存在争议。该公司受益于基于订阅的商业模式，但也面临来自美国联邦合同依赖和竞争的风险。Simply Wall St 提供分析，但不提供财务建议</p>

<p>Cellebrite DI (NasdaqGS:CLBT) just delivered a quarterly update that the market clearly liked, with shares jumping about 20% as investors responded to stronger execution and accelerating momentum in its Guardian investigative platform.</p>
<div class="lb-trans"><p>Cellebrite DI（纳斯达克代码：CLBT）刚刚发布了季度更新，市场对此反应热烈，股价上涨约 20%，投资者对其在 Guardian 调查平台上的强劲执行和加速势头表示满意。</p>
</div><p>See our latest analysis for Cellebrite DI.</p>
<div class="lb-trans"><p>查看我们对 Cellebrite DI 的最新分析。</p>
</div><p>That earnings pop sits on top of a 1 month share price return of 18.7% and a 90 day gain of 7%, even though the year to date share price return is still negative and the 1 year total shareholder return is slightly in the red. At the same time, the 3 year total shareholder return above 300% shows how powerful the longer term story has been and suggests momentum is rebuilding as investors refocus on Guardian growth, Corellium integration, and potential federal and NATO related upside.</p>
<div class="lb-trans"><p>这次盈利的激增是在过去一个月股价回报 18.7% 和 90 天涨幅 7% 的基础上，尽管年初至今的股价回报仍为负值，且一年期的总股东回报略有亏损。同时，三年期总股东回报超过 300% 显示出长期故事的强大，暗示随着投资者重新关注 Guardian 的增长、Corellium 的整合以及潜在的联邦和北约相关的上行空间，势头正在重建。</p>
</div><p>If Cellebrite’s run has you rethinking your opportunity set, this could be a smart moment to explore high growth tech and AI stocks that are shaping the next wave of digital investigation and defense technology.</p>
<div class="lb-trans"><p>如果 Cellebrite 的表现让你重新考虑投资机会，这可能是探索高增长科技和人工智能股票的好时机，这些股票正在塑造下一波数字调查和防御技术。</p>
</div><p>With revenue and earnings still compounding and the stock trading at a sizeable discount to analyst targets, the key question now is whether this reset leaves CLBT undervalued or if markets are already pricing in the next leg of growth.</p>
<div class="lb-trans"><p>随着收入和盈利仍在复合增长，且股票交易价格大幅低于分析师目标价，关键问题是此次重置是否使 CLBT 被低估，还是市场已经在定价下一轮增长。</p>
</div><h2>Most Popular Narrative Narrative: 26% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：26% 被低估</h2>
</div><p>With the narrative fair value sitting at $24.71 against a last close of $18.28, the valuation case leans heavily on faster growth and higher margins.</p>
<div class="lb-trans"><p>叙述的公允价值为 24.71 美元，而最后收盘价为 18.28 美元，估值案例在很大程度上依赖于更快的增长和更高的利润率。</p>
</div><blockquote>
<p><em>The continued transition to a recurring, subscription-based revenue model, with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration, improves revenue visibility, predictability, and operating leverage. This is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>持续向基于订阅的经常性收入模式转型，现有超过 90% 的收入来自订阅，且 SaaS/云渗透率不断提高，改善了收入的可见性、可预测性和运营杠杆。这已经转化为更高的 EBITDA 和自由现金流利润率，且在当前估值中可能被低估。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>To see the math behind that confidence gap, including the growth runway, margin expansion, and the future earnings multiple incorporated in this story, explore the full narrative.</p>
<div class="lb-trans"><p>要了解这种信心差距背后的数学，包括增长前景、利润率扩张和未来收益倍数，探索完整叙述。</p>
</div><p><strong>Result: Fair Value of $24.71 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 24.71 美元（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, heavy dependence on US federal contracts and intensifying competition in lawful access tools could slow ARR growth and compress the premium valuation case.</p>
<div class="lb-trans"><p>然而，对美国联邦合同的高度依赖以及在合法访问工具中日益激烈的竞争可能会减缓 ARR 增长并压缩溢价估值案例。</p>
</div><p>Find out about the key risks to this Cellebrite DI narrative.</p>
<div class="lb-trans"><p>了解 Cellebrite DI 叙述的关键风险。</p>
</div><h2>Another Way to Look at Value</h2>
<div class="lb-trans"><h2>另一种看待价值的方法</h2>
</div><p>While the narrative suggests Cellebrite is 26% undervalued, our SWS DCF model sees things differently, with a fair value closer to $13.51 versus the $18.28 share price. This implies the stock is actually overvalued. Which lens do you trust more for the next move?</p>
<div class="lb-trans"><p>虽然叙述表明 Cellebrite 被低估 26%，但我们的 SWS DCF 模型则有不同看法，公允价值接近 13.51 美元，而当前股价为 18.28 美元。这意味着该股票实际上被高估。你更信任哪个视角来判断下一步？</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>深入了解 SWS DCF 模型如何得出其公允价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3faf6e74-6124-464a-beb5-e211fb138330/chart/dcf" alt="" original-src="https://images.simplywall.st/company/3faf6e74-6124-464a-beb5-e211fb138330/chart/dcf"/></p>
<p>CLBT Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 CLBT 折现现金流</p>
</div><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cellebrite DI for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 907 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p>
<div class="lb-trans"><p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看 Cellebrite DI）。我们展示了完整的计算过程。你可以在你的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 907 只基于现金流的被低估股票。如果你保存一个筛选器，我们甚至会在新公司匹配时提醒你——这样你就不会错过潜在机会。</p>
</div><h2>Build Your Own Cellebrite DI Narrative</h2>
<div class="lb-trans"><h2>构建你自己的 Cellebrite DI 叙述</h2>
</div><p>If this outlook does not fully align with your own views, dive into the numbers yourself and build a tailored narrative in minutes, Do it your way.</p>
<div class="lb-trans"><p>如果这个前景与你的观点不完全一致，自己深入数字，几分钟内构建一个量身定制的叙述，按你的方式进行。</p>
</div><p>A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Cellebrite DI.</p>
<div class="lb-trans"><p>一个好的起点是我们的分析，强调投资者对 Cellebrite DI 的三个关键回报的乐观态度。</p>
</div><h2>Ready for more investment ideas?</h2>
<div class="lb-trans"><h2>准备好更多投资想法了吗？</h2>
</div><p>Before the market’s next big move leaves you watching from the sidelines, put your research to work and line up your next opportunity using targeted screeners.</p>
<div class="lb-trans"><p>在市场下一个重大变动让你旁观之际，利用你的研究工作，排定下一个机会，使用针对性的筛选器。</p>
</div><ul>
<li>Capitalize on potential mispricing by reviewing these 907 undervalued stocks based on cash flows that pair strong fundamentals with attractive valuations before sentiment fully catches up.</li>
<li>Explore structural growth trends by focusing on these 30 healthcare AI stocks that support diagnostics, patient outcomes, and hospital efficiency in the coming decade.</li>
<li>Prepare for financial innovation by evaluating these 81 cryptocurrency and blockchain stocks that build real businesses around blockchain infrastructure, payments, and digital asset networks.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过审查这些 907 只基于现金流的被低估股票，利用潜在的错误定价，这些股票将强大的基本面与有吸引力的估值相结合，在情绪完全追赶之前。</li>
<li>通过关注这 30 只支持诊断、患者结果和医院效率的医疗 AI 股票，探索结构性增长趋势，这些股票将在未来十年内发挥作用。</li>
<li>通过评估这 81 只围绕区块链基础设施、支付和数字资产网络构建真实业务的加密货币和区块链股票，为金融创新做好准备。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容一般。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

Cellebrite DI（纳斯达克股票代码：CLBT）：在财报广受好评以及 Guardian 平台增长之后重新评估其估值